Is SAB Biotherapeutics, Inc. (SABS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.6% / 30% | 11.5% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 2.6% / 33% | 11.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 10.6% / 33% | 47.0% / 33% | 0.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.6% / 33% | 11.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 10.6% / 33% | 47.0% / 33% | 0.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | 15.0% | |
| Return on Assets (ROA) | -28.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$45M |
| Free Cash Flow | -$46M |
| Total Debt | $6M |
| Debt-to-Equity | 3.9 |
| Current Ratio | 9.5 |
| Total Assets | $173M |
Price & Trading
| Last Close | $3.83 |
| 50-Day MA | $4.03 |
| 200-Day MA | $3.07 |
| Avg Volume | 525K |
| Beta | 0.6 |
|
52-Week Range
$1.00
| |
About SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is SAB Biotherapeutics, Inc. (SABS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), SAB Biotherapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is SAB Biotherapeutics, Inc.'s debt ratio?
SAB Biotherapeutics, Inc.'s debt ratio is 2.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.6%.
What are SAB Biotherapeutics, Inc.'s key financial metrics?
SAB Biotherapeutics, Inc. has a market capitalization of $271M. Return on equity stands at 15.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.